SCHEMBL997862

SCHEMBL997862

Cc1cc(C)cc(NC(=O)N2C(c3cccc(F)c3)c3[nH]c4ccncc4c3CC23CC3)c1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 3/20 0.41
CYP3A4 P08684 5/20 0.36
CYP2D6 P10635 2/20 0.36
CYP2C19 P33261 2/20 0.36
MAPK1 P28482 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TP53 P04637 5/20 0.34
USP2 O75604 1/20 0.34
ALOX15 P16050 1/20 0.34
MAPT P10636 2/20 0.34
ALDH1A1 P00352 2/20 0.33
ESR1 P03372 1/20 0.33
POLB P06746 1/20 0.33
KDM4E B2RXH2 1/20 0.33
TSHR P16473 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
DRD4 P21917 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL998662 0.94 KIF11 (0.39) KIF11CYP3A4CYP2D6CYP2C19MAPK1
SCHEMBL998098 0.87 KIF11 (0.37) KIF11CYP3A4CYP2D6CYP2C19MAPK1
SCHEMBL996764 0.87 KIF11 (0.36) KIF11CYP3A4CYP2D6CYP2C19MAPK1
SCHEMBL998181 0.86 KIF11 (0.42) KIF11MAPK1TP53MAPTALDH1A1
SCHEMBL998567 0.85 KIF11 (0.40) KIF11CYP2D6CYP2C19MAPK1SMN1; SMN2
SCHEMBL999384 0.85 KIF11 (0.37) KIF11CYP3A4CYP2D6CYP2C19MAPK1
SCHEMBL996597 0.85 KIF11 (0.39) KIF11CYP3A4CYP2D6CYP2C19MAPK1
SCHEMBL998439 0.85 KIF11 (0.37) KIF11CYP3A4CYP2D6CYP2C19MAPK1
SCHEMBL998307 0.84 KIF11 (0.55) KIF11TP53MAPTPOLB
SCHEMBL996806 0.82 KIF11 (0.41) KIF11CYP3A4CYP2D6CYP2C19MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872133-B2 Tricyclic heterocycle compound ONO PHARMACEUTICAL CO., LTD. (JP) 2011-01-18 US disclosed
US-20060154944-A1 Novel tricyclic heterocycle compound ONO PHARMACEUTICAL CO., LTD. (JP) 2006-07-13 US disclosed
EP-1637521-A1 NOVEL TRICYCLIC HETEROCYCLE COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2006-03-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154944-A1 Novel tricyclic heterocycle compound CYP11B1, CYP11B2, HCCS KIF11 4760/4885CYP3A4 709/4885CYP2D6 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.